ATE129160T1 - Herpes-simplex-impfstoff, der hsv-glycoprotein-gd und 3-deacyl monophosphoryl-lipid-a enthaelt. - Google Patents
Herpes-simplex-impfstoff, der hsv-glycoprotein-gd und 3-deacyl monophosphoryl-lipid-a enthaelt.Info
- Publication number
- ATE129160T1 ATE129160T1 AT92906441T AT92906441T ATE129160T1 AT E129160 T1 ATE129160 T1 AT E129160T1 AT 92906441 T AT92906441 T AT 92906441T AT 92906441 T AT92906441 T AT 92906441T AT E129160 T1 ATE129160 T1 AT E129160T1
- Authority
- AT
- Austria
- Prior art keywords
- herpes simplex
- monophosphoryl lipid
- vaccine containing
- hsv glycoprotein
- containing hsv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9105992A GB9105992D0 (en) | 1991-03-21 | 1991-03-21 | Vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE129160T1 true ATE129160T1 (de) | 1995-11-15 |
Family
ID=10691946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT92906441T ATE129160T1 (de) | 1991-03-21 | 1992-03-17 | Herpes-simplex-impfstoff, der hsv-glycoprotein-gd und 3-deacyl monophosphoryl-lipid-a enthaelt. |
Country Status (34)
Country | Link |
---|---|
US (1) | US6027730A (de) |
EP (1) | EP0576478B2 (de) |
JP (1) | JP3530526B2 (de) |
KR (1) | KR100224329B1 (de) |
CN (2) | CN1058191C (de) |
AP (1) | AP298A (de) |
AT (1) | ATE129160T1 (de) |
AU (1) | AU650521B2 (de) |
BR (1) | BR9205745A (de) |
CA (1) | CA2106492C (de) |
CY (1) | CY1936A (de) |
CZ (1) | CZ280505B6 (de) |
DE (1) | DE69205566T3 (de) |
DK (1) | DK0576478T4 (de) |
ES (1) | ES2081102T5 (de) |
FI (1) | FI107881B (de) |
GB (1) | GB9105992D0 (de) |
GR (1) | GR3017884T3 (de) |
HK (1) | HK1004525A1 (de) |
HU (1) | HU218025B (de) |
IE (1) | IE69560B1 (de) |
IL (1) | IL101290A (de) |
MA (1) | MA22471A1 (de) |
MX (1) | MX9201245A (de) |
MY (1) | MY110086A (de) |
NO (1) | NO307499B1 (de) |
NZ (1) | NZ242057A (de) |
PL (1) | PL170059B1 (de) |
PT (1) | PT100262B (de) |
SA (1) | SA92120459B1 (de) |
SK (1) | SK279190B6 (de) |
WO (1) | WO1992016231A1 (de) |
YU (1) | YU28392A (de) |
ZA (1) | ZA922011B (de) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9105992D0 (en) * | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
US6197311B1 (en) | 1991-07-25 | 2001-03-06 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
GB9202933D0 (en) * | 1992-02-12 | 1992-03-25 | Smithkline Beecham Biolog | Vaccines |
US6620414B2 (en) | 1992-03-27 | 2003-09-16 | Smithkline Beecham Biologicals (S.A.) | Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A |
CA2156525A1 (en) * | 1993-02-19 | 1994-09-01 | Susan Dillon | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
PL178578B1 (pl) * | 1993-03-23 | 2000-05-31 | Smithkline Beecham Biolog | Zawiesina cząstek 3-0-deacylowanego monofosforylolipidu A i sposób jej wytwarzania oraz kompozycja szczepionki zawierającej antygen w połączeniu z 3-0-deacylowanym monofosforylolipidem A i sposób jej wytwarzania |
ES2150493T5 (es) * | 1993-05-25 | 2004-07-01 | Wyeth Holdings Corporation | Adyuvantes para vacunas contra el virus sincitico respiratorio. |
GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
JPH10511846A (ja) | 1994-12-28 | 1998-11-17 | ユニバーシティ オブ ケンタッキー | ヒトガン胎児性抗原に関連する組換えモノクローナル抗イディオタイプ抗体3h1配列 |
US6949244B1 (en) | 1995-12-20 | 2005-09-27 | The Board Of Trustees Of The University Of Kentucky | Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof |
US6235280B1 (en) | 1996-04-12 | 2001-05-22 | Malaya Chatterjee | Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1 |
US20020041872A1 (en) | 1996-04-12 | 2002-04-11 | Malaya Chatterjee | Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1 |
US6468782B1 (en) | 1996-12-05 | 2002-10-22 | Quadrant Healthcare (Uk) Limited | Methods of preserving prokaryotic cells and compositions obtained thereby |
US6274143B1 (en) | 1997-06-13 | 2001-08-14 | Malaya Chatterjee | Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10 |
US6355244B1 (en) | 1997-11-17 | 2002-03-12 | University Of Kentucky Research Foundation | Methods and compositions for the treatment of psoriasis |
GB9819898D0 (en) * | 1998-09-11 | 1998-11-04 | Smithkline Beecham Plc | New vaccine and method of use |
US6692752B1 (en) * | 1999-09-08 | 2004-02-17 | Smithkline Beecham Biologicals S.A. | Methods of treating human females susceptible to HSV infection |
CA2347099C (en) | 1998-10-16 | 2014-08-05 | Smithkline Beecham Biologicals S.A. | Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof |
US7026155B2 (en) | 1999-02-02 | 2006-04-11 | Regents Of The University Of California | Method of reducing bacterial proliferation |
EP1104767A1 (de) | 1999-11-30 | 2001-06-06 | Stichting Dienst Landbouwkundig Onderzoek | Mono- und Disaccharidederivate die sowohl Fettsäureestern als Sulfatestern enthalten |
US9273326B2 (en) | 2004-04-30 | 2016-03-01 | The Brigham And Women's Hospital, Inc. | Tetracycline-regulated gene expression in HSV-1 vectors |
NZ553776A (en) | 2004-09-22 | 2010-05-28 | Glaxosmithkline Biolog Sa | Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide. |
CA2601022C (en) | 2005-03-23 | 2023-03-07 | Glaxosmithkline Biologicals S.A. | Use of an influenza virus an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response |
GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
EP3020411A1 (de) | 2005-12-22 | 2016-05-18 | GlaxoSmithKline Biologicals s.a. | Impfstoff |
EP1998802A2 (de) | 2006-03-30 | 2008-12-10 | GlaxoSmithKline Biologicals S.A. | Immunogene zusammensetzung |
JP5639760B2 (ja) | 2006-07-17 | 2014-12-10 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | インフルエンザワクチン |
DK2068918T4 (da) | 2006-09-26 | 2024-09-02 | Access To Advanced Health Inst | Vaccinesammensætning omfattende syntetisk adjuvant |
US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
TW200908994A (en) | 2007-04-20 | 2009-03-01 | Glaxosmithkline Biolog Sa | Vaccine |
PT2167121E (pt) | 2007-06-26 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vacina compreendendo conjugados de polissacáridos capsulares de streptococcus pneumoniae |
EP3590533A1 (de) | 2009-05-22 | 2020-01-08 | Genocea Biosciences, Inc. | Impfstoffe gegen den herpes-simplex-virus vom typ 2: zusammensetzungen und verfahren zur auslösung einer immunreaktion |
EP3124491B1 (de) * | 2009-06-05 | 2019-10-30 | Infectious Disease Research Institute | Synthetische glucopyranosyl-lipid-adjuvanzien und impfstoffzusammensetzungen sowie pharmazeutische zusammensetzungen die diese enthalten |
GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
RS54933B1 (sr) | 2009-12-21 | 2016-10-31 | Brigham & Womens Hospital Inc | Vakcine herpes simpleks virusa |
EP2643014A4 (de) | 2010-11-24 | 2015-11-11 | Genocea Biosciences Inc | Impfstoffe gegen den herpes-simplex-virus vom typ 2: zusammensetzungen und verfahren zur auslösung einer immunreaktion |
CN108126204A (zh) * | 2011-03-11 | 2018-06-08 | 特斯通有限责任合伙公司 | 包含组蛋白去乙酰化酶抑制剂的疫苗接种方法 |
JP6054942B2 (ja) | 2011-04-08 | 2016-12-27 | イミューン デザイン コーポレイション | 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法 |
CA2845872C (en) | 2011-08-22 | 2023-03-28 | Nanobio Corporation | Herpes simplex virus nanoemulsion vaccine |
CA2885693C (en) | 2011-11-23 | 2020-07-28 | Genocea Biosciences, Inc. | Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response |
CN107540730B (zh) | 2012-05-16 | 2021-07-16 | 免疫设计公司 | 用于hsv-2的疫苗 |
DK2941269T3 (da) | 2013-01-07 | 2021-01-11 | Mucosal Vaccine Tech Llc | Terapeutiske vacciner til behandling af herpes simplex-virus type 2-infektioner |
BR112015025709A2 (pt) | 2013-04-18 | 2017-07-18 | Immune Design Corp | monoterapia com gla para uso em tratamento de câncer |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
WO2018064232A1 (en) | 2016-09-28 | 2018-04-05 | Genocea Biosciences, Inc. | Methods and compositions for treating herpes |
WO2019152821A1 (en) | 2018-02-05 | 2019-08-08 | The Brigham And Women's Hospital, Inc. | Recombinant herpes simplex virus-2 expressing glycoprotein b and d antigens |
WO2022152939A1 (en) | 2021-01-18 | 2022-07-21 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4372945A (en) * | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) * | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
US5110587A (en) * | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US4762708A (en) * | 1982-02-18 | 1988-08-09 | University Patents, Inc. | Materials and methods for herpes simplex virus vaccination |
US5149660A (en) * | 1982-02-18 | 1992-09-22 | University Patents, Inc. | Diagnostic reagents relating to herpes simplex virus |
NZ209308A (en) * | 1983-08-30 | 1991-08-27 | Genentech Inc | Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein |
US5244792A (en) * | 1984-04-06 | 1993-09-14 | Chiron Corporation | Expression of recombinant glyoprotein B from herpes simplex virus |
US5171568A (en) * | 1984-04-06 | 1992-12-15 | Chiron Corporation | Recombinant herpes simplex gb-gd vaccine |
US4877611A (en) * | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US5554372A (en) * | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
EP0289550B1 (de) * | 1986-10-20 | 1996-04-10 | Chiron Corporation | Impfstoff zur behandlung von hsv |
US5149529A (en) * | 1988-04-08 | 1992-09-22 | Board Of Trustees Of Leland Chiron Corporation | Compositions and treatment for herpes simplex |
US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
NZ230424A (en) * | 1988-08-25 | 1992-05-26 | Liposome Co Inc | Liposomal composition comprising an externally disposed antigen |
EP0440742B1 (de) * | 1988-10-27 | 1997-01-15 | The Regents Of The University Of Minnesota | Immunhilfsmittel aus Liposome enthaltend Lymphokin IL -2 |
US5597573A (en) * | 1989-05-04 | 1997-01-28 | Igen, Inc. | Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities |
US5158939A (en) * | 1989-07-21 | 1992-10-27 | Wisconsin Alumni Research Foundation | Method of stimulating the immune systems of animals and compositions useful therefor |
WO1991001146A1 (en) * | 1989-07-14 | 1991-02-07 | Praxis Biologics, Inc. | Cytokine and hormone carriers for conjugate vaccines |
ES2144400T3 (es) * | 1990-08-01 | 2000-06-16 | Res Corp Technologies Inc | Gen que codifica la gliproteina d del virus del herpes equino de tipo 1, su producto genico, anticuerpos y su utilizacion. |
JP3005292B2 (ja) * | 1990-08-02 | 2000-01-31 | カイロン コーポレイション | 単純ヘルペスウィルスのvp16のワクチン |
GB9106048D0 (en) * | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccines |
US5196452A (en) * | 1991-01-29 | 1993-03-23 | Genelabs Incorporated | Macrocyclic anti-viral compound and method |
US5166173A (en) * | 1991-01-29 | 1992-11-24 | Genelabs Incorporated | Method of treating herpes simplex virus infection |
GB9105992D0 (en) * | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
MA22842A1 (fr) * | 1992-03-27 | 1993-10-01 | Smithkline Beecham Biolog | Procede de preparation de compositions de vaccin. |
NZ253137A (en) * | 1992-06-25 | 1996-08-27 | Smithkline Beecham Biolog | Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a. |
CA2156525A1 (en) * | 1993-02-19 | 1994-09-01 | Susan Dillon | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
PL178578B1 (pl) * | 1993-03-23 | 2000-05-31 | Smithkline Beecham Biolog | Zawiesina cząstek 3-0-deacylowanego monofosforylolipidu A i sposób jej wytwarzania oraz kompozycja szczepionki zawierającej antygen w połączeniu z 3-0-deacylowanym monofosforylolipidem A i sposób jej wytwarzania |
ES2150493T5 (es) * | 1993-05-25 | 2004-07-01 | Wyeth Holdings Corporation | Adyuvantes para vacunas contra el virus sincitico respiratorio. |
-
1991
- 1991-03-21 GB GB9105992A patent/GB9105992D0/en active Pending
-
1992
- 1992-03-17 KR KR1019930702835A patent/KR100224329B1/ko not_active IP Right Cessation
- 1992-03-17 AU AU13657/92A patent/AU650521B2/en not_active Expired
- 1992-03-17 JP JP50598492A patent/JP3530526B2/ja not_active Expired - Lifetime
- 1992-03-17 ES ES92906441T patent/ES2081102T5/es not_active Expired - Lifetime
- 1992-03-17 PL PL92300617A patent/PL170059B1/pl unknown
- 1992-03-17 CA CA 2106492 patent/CA2106492C/en not_active Expired - Lifetime
- 1992-03-17 BR BR9205745A patent/BR9205745A/pt not_active Application Discontinuation
- 1992-03-17 CY CY193692A patent/CY1936A/xx unknown
- 1992-03-17 DE DE69205566T patent/DE69205566T3/de not_active Expired - Lifetime
- 1992-03-17 AT AT92906441T patent/ATE129160T1/de active
- 1992-03-17 SK SK946-93A patent/SK279190B6/sk unknown
- 1992-03-17 HU HU9302645A patent/HU218025B/hu unknown
- 1992-03-17 DK DK92906441T patent/DK0576478T4/da active
- 1992-03-17 EP EP19920906441 patent/EP0576478B2/de not_active Expired - Lifetime
- 1992-03-17 CZ CS931958A patent/CZ280505B6/cs not_active IP Right Cessation
- 1992-03-17 WO PCT/EP1992/000592 patent/WO1992016231A1/en active IP Right Grant
- 1992-03-18 MY MYPI92000448A patent/MY110086A/en unknown
- 1992-03-19 CN CN92102950A patent/CN1058191C/zh not_active Expired - Lifetime
- 1992-03-19 IL IL10129092A patent/IL101290A/en not_active IP Right Cessation
- 1992-03-19 ZA ZA922011A patent/ZA922011B/xx unknown
- 1992-03-19 NZ NZ242057A patent/NZ242057A/en not_active IP Right Cessation
- 1992-03-19 IE IE920881A patent/IE69560B1/en not_active IP Right Cessation
- 1992-03-19 PT PT100262A patent/PT100262B/pt not_active IP Right Cessation
- 1992-03-19 MA MA22760A patent/MA22471A1/fr unknown
- 1992-03-20 YU YU28392A patent/YU28392A/sh unknown
- 1992-03-20 MX MX9201245A patent/MX9201245A/es unknown
- 1992-03-20 AP APAP/P/1992/000368A patent/AP298A/en active
- 1992-04-21 SA SA92120459A patent/SA92120459B1/ar unknown
-
1993
- 1993-09-20 NO NO933343A patent/NO307499B1/no not_active IP Right Cessation
- 1993-09-21 FI FI934134A patent/FI107881B/fi not_active IP Right Cessation
-
1994
- 1994-09-09 US US08/303,542 patent/US6027730A/en not_active Expired - Lifetime
-
1995
- 1995-10-25 GR GR950402992T patent/GR3017884T3/el unknown
-
1998
- 1998-01-05 CN CN98103933A patent/CN1101226C/zh not_active Expired - Lifetime
- 1998-04-28 HK HK98103623A patent/HK1004525A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE129160T1 (de) | Herpes-simplex-impfstoff, der hsv-glycoprotein-gd und 3-deacyl monophosphoryl-lipid-a enthaelt. | |
CY2007015I1 (el) | Εμβολιο ιου θηλωματος | |
DE3685847D1 (de) | Infrarot projektoranordnung. | |
AP9100332A0 (en) | Vaccines | |
OA08199A (en) | Vaccine. | |
OA08200A (en) | Vaccine. | |
CY2008005I2 (el) | Εμβολιο κατα της παρωτιτιδας που περιεχει στελεχος ιου jeryl-lynn | |
EP0595970A4 (de) | Verbesserter impfstoff. | |
EP0236487A4 (de) | Virus-inaktivierung. | |
EP0266401A4 (de) | Impfstoffe. | |
GB9125896D0 (en) | Bicistronic viruses | |
HU9203976D0 (en) | Vaccine based on modified herpes virus | |
EP0570462A4 (de) | Abgeändertes interleukin-1beta. | |
GB8602706D0 (en) | Non-linear optics | |
GB8602708D0 (en) | Non-linear optics | |
ZA939564B (en) | Vaccines. | |
GB9225535D0 (en) | Bicistronic viruses | |
EP0225329A4 (de) | Impfstoff ohne hilfsmittel. | |
EP0681480A4 (de) | Recognin vakzine. | |
ZA924670B (en) | Ccv vaccine | |
EP0621893A4 (de) | Impfstoffe gegen den leukämievirus der katze. | |
FI923350A0 (fi) | Foerfarande foer maerkning av substanser med teknetium eller renium. | |
DE3768117D1 (de) | Transportsicherung. | |
GB9324964D0 (en) | Viral vaccines | |
GB9305710D0 (en) | Viral vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
UEP | Publication of translation of european patent specification |